CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+7.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$162M
(+18%)
Cap. Flow
+$137M
Cap. Flow
% of AUM
12.79%
Top 10 Holdings %
Top 10 Hldgs %
37.33%
Holding
532
New
105
Increased
323
Reduced
47
Closed
36
Top Buys
| 1 |
Apple
AAPL
|
$9.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$7.06M |
| 3 |
NVIDIA
NVDA
|
$6.46M |
| 4 |
Microsoft
MSFT
|
$6.23M |
| 5 |
ProShares Ultra Gold
UGL
|
$5.73M |
Top Sells
| 1 |
Alibaba
BABA
|
$5.72M |
| 2 |
GSK
GSK
|
$5.14M |
| 3 |
Pinduoduo
PDD
|
$3.46M |
| 4 |
Procter & Gamble
PG
|
$2.91M |
| 5 |
Synopsys
SNPS
|
$2.45M |
Sector Composition
| 1 | Technology | 38.06% |
| 2 | Healthcare | 25.43% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Communication Services | 10.24% |
| 5 | Financials | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
451
Walt Disney
DIS
$212B
| $49.6K | ﹤0.01% |
444
-4,199
| -90% | -$469K |
|
452
Inhibrx
INBX
$408M
| $47.3K | ﹤0.01% |
+3,069
| New | +$47.3K |
|
453
Lexeo Therapeutics
LXEO
$271M
| $46.1K | ﹤0.01% |
+7,011
| New | +$46.1K |
|
|
IGMS
454
DELISTED
IGM Biosciences
IGMS
| $44.2K | ﹤0.01% |
+7,226
| New | +$44.2K |
|
455
Texas Roadhouse
TXRH
$11.2B
| $44K | ﹤0.01% |
244
| – | – |
|
456
MacroGenics
MGNX
$126M
| $43.3K | ﹤0.01% |
13,308
+1,244
| +10% | +$4.04K |
|
|
AMRN
457
Amarin Corp
AMRN
$317M
| $41.2K | ﹤0.01% |
4,243
+395
| +10% | +$3.83K |
|
|
CMPS
458
Compass Pathways
CMPS
$493M
| $40.8K | ﹤0.01% |
+10,782
| New | +$40.8K |
|
459
Fate Therapeutics
FATE
$116M
| $39.8K | ﹤0.01% |
+24,150
| New | +$39.8K |
|
460
Acrivon Therapeutics
ACRV
$41.8M
| $39.7K | ﹤0.01% |
+6,602
| New | +$39.7K |
|
461
Alector
ALEC
$305M
| $39.2K | ﹤0.01% |
20,765
+2,047
| +11% | +$3.87K |
|
462
Tevogen Bio Holdings
TVGN
$170M
| $38.2K | ﹤0.01% |
+37,117
| New | +$38.2K |
|
463
Lyell Immunopharma
LYEL
$233M
| $37.9K | ﹤0.01% |
2,960
+498
| +20% | +$6.38K |
|
|
INZY
464
DELISTED
Inozyme Pharma
INZY
| $37.7K | ﹤0.01% |
+13,621
| New | +$37.7K |
|
465
Hyatt Hotels
H
$13.8B
| $37.7K | ﹤0.01% |
240
| – | – |
|
466
scPharmaceuticals
SCPH
$299M
| $37.6K | ﹤0.01% |
+10,610
| New | +$37.6K |
|
467
Mersana Therapeutics
MRSN
$34M
| $37.5K | ﹤0.01% |
+1,048
| New | +$37.5K |
|
468
Nkarta
NKTX
$161M
| $37.3K | ﹤0.01% |
+14,963
| New | +$37.3K |
|
469
Kyverna Therapeutics
KYTX
$170M
| $34.2K | ﹤0.01% |
+9,154
| New | +$34.2K |
|
470
Solid Biosciences
SLDB
$428M
| $33.9K | ﹤0.01% |
+8,472
| New | +$33.9K |
|
471
Sutro Biopharma
STRO
$89.9M
| $32.2K | ﹤0.01% |
+17,484
| New | +$32.2K |
|
|
472
GSK
GSK
$81.5B
| $32.2K | ﹤0.01% |
338
-54,007
| -99% | -$5.14M |
|
|
TSVT
473
DELISTED
2seventy bio
TSVT
| $32.2K | ﹤0.01% |
+10,939
| New | +$32.2K |
|
474
TScan Therapeutics
TCRX
$108M
| $31.6K | ﹤0.01% |
+10,410
| New | +$31.6K |
|
475
Deckers Outdoor
DECK
$17.9B
| $30.5K | ﹤0.01% |
150
| – | – |
|